Quick facts
- The Ministry of Health has extended the RSV prevention program for infants and high-risk children into .
- Please continue to administer nirsevimab (Beyfortus®) to eligible infants and high-risk children (external link) until the Ministry circulates communication to mark the end of the program.
- For maternal vaccination, consider the timing of administration during pregnancy (i.e. between gestation) and the upcoming timing for the end of the season.
Key messages for healthcare providers
- The Ministry of Health program materials indicate that the RSV season generally concludes at the end of March. However, based on epidemiological data, community transmission of RSV is ongoing and positivity across the province remains high, particularly among infants and children.
- As a result, the RSV prevention program for infants and high-risk children will extend into .
- Infants born at Halton hospitals will continue to be offered nirsevimab prior to discharge.
- Please continue to administer nirsevimab to eligible infants and high-risk children until you receive communication to mark the end of the program.
- While nirsevimab is the preferred product for infant protection, Abrysvo™ is authorized for use in pregnant individuals between gestation who are expected to deliver during the RSV season.
- The decision to administer maternal vaccination should take into consideration the timing of administration during pregnancy (i.e. between gestation) and the upcoming timing for the end of the season.
- To order RSV products, fax a completed RSV Product Order Form (PDF file) to 905-465-3403.
- Guidance for the program will be provided leading up to the fall and will include recommendations for those infants and children who receive RSV protection late this season.
Additional resources
Infant and High-Risk Children RSV Prevention Program (external link), Ontario Ministry of Health